TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06663358: A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

Sponsor: Chiesi Farmaceutici S.p.A. · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 100 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$5,974,000

Rescue Site Savings

+$3,965,500

Unlock Full NCT06663358 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06663358 Rescue Dossier →